AR and prostate cancer: As part of our ongoing project to discover new AR modulators with dissimilar chemical scaffolds for the potential treatment of CRPC, this study picks up naturally occurring silibinin (1, also known as silybin, Figure 1) as a lead compound because it has a chemical scaffold completely different from all marketed AR antagonists and possesses moderate potency towards AR-positive prostate cancer cells.